I'm LongbridgeAI. Here is the key information I extracted- This surge reflects a major shift in market recognition of local pharmaceutical companies' innovation capabilities, with expectations that the Federal Reserve's accelerated rate cuts will enhance risk appetite and direct funds towards growth sectors like Chinese biotech. …
According to the Zhitong Finance APP, Morgan Stanley released a research report stating that the total market value of Chinese biotech stocks listed in Hong Kong has increased by 154% year-to-date, far exceeding the Hang Seng Index's increase of 34% during the same period. This is believed to reflect a significant change in the market's recognition of the innovation capabilities of domestic pharmaceutical companies. It is expected that the Federal Reserve's accelerated pace of interest rate cuts will drive a shift in risk appetite, directing funds towards growth sectors such as Chinese biotech.
However, Morgan Stanley anticipates that the performance of individual stocks will still depend on the company's fundamentals, including commercialization execution and innovation research and development progress. They are optimistic about companies with short-term catalysts, such as AKESO (09926), INNOCARE (09969), ABBISKO-B (02256), INNOVENT BIO (01801), and YINGEN BIO-B (09606). Additionally, they have given a "Outperform" rating to VISION PHARMA-B (02561) and ZAI LAB (09688)